Annette Weiss

Annette Weiss

Auto-generated profile, based on publicly available information

Annette Weiss

Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2016 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AWAnnette Weiss
Annette Weiss
GSGrit Sommer
Grit Sommer
RKRahel Kasteler
Rahel Kasteler
KSKatrin Scheinemann
Katrin Scheinemann
MGMichael Grotzer
Michael Grotzer
F(for the Swiss Pediatric Oncology Group (SPOG)
for the Swiss Pediatric Oncology Group (SPOG)

26 January 2018 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
FBFabiën Belle
Fabiën Belle
AWAnnette Weiss
Annette Weiss
MSMatthias Schindler
Matthias Schindler
MGMyrofora Goutaki
Myrofora Goutaki
Murielle BochudMurielle Bochud
Murielle Bochud
CKClaudia E. Kuehni
Claudia E. Kuehni
An increased risk of becoming overweight has been reported for childhood cancer survivors (CCSs), in particular leukemia survivors, although the evidence is inconclusive. We assessed the prevalence of overweight in CCSs, with a focus on leukemia survivors, compared it with their peers, and determined potential risk factors. As part of the Swiss Childhood Cancer Survivor Study, we sent a questionnaire between 2007 and 2013 to all Swiss resident CCSs aged <21 y at diagnosis who had survived ≥5 y. We calculated body mass index (BMI) from medical records at diagnosis and self-reported heights and weights at survey. We calculated BMI z scores by using Swiss references for children and compared overweight prevalence in CCSs, their siblings, and the general population with the use of the Swiss Health Survey (SHS) and assessed risk factors for being overweight by using multivariable logistic regression. The study included 2365 CCSs, 819 siblings, and 9591 SHS participants. At survey, at an average of 15 y after diagnosis, the prevalence of overweight in CCSs overall (26%) and in leukemia survivors (26%) was similar to that in siblings (22%) and the general population (25%). Risk factors for being overweight in CCSs were male sex (OR: 1.8; 95% CI: 1.5, 2.1), both young (OR for ages 5–14 y: 1.6; 95% CI: 1.2, 2.3) and older (range—OR for ages 25–29 y: 1.7; 95% CI: 1.2, 2.4; OR for ages 40–45 y: 4.0; 95% CI: 2.5, 6.5) age at study, lower education (OR: 1.4; 95% CI: 1.1, 1.8), migration background (OR: 1.3; 95% CI: 1.1, 1.7), and no sports participation (OR: 1.4; 95% CI: 1.1, 1.7). Risk factors for overweight were similar in peers. CCSs treated with cranial radiotherapy (≥20 Gy) were more likely to be overweight than their peers (OR: 1.6; 95% CI: 1.2, 2.2). The prevalence of and risk factors for being overweight are similar in long-term CCSs and their peers. This suggests that prevention methods can be the same as in the general population. An important exception is CCSs treated with cranial radiotherapy ≥20 Gy who may need extra attention during follow-up care. This study was registered at clinicaltrials.gov as NCT03297034.

20 November 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CSChristina Schindera
Christina Schindera
AWAnnette Weiss
Annette Weiss
NHNiels Hagenbuch
Niels Hagenbuch
Maria OtthMaria Otth
Maria Otth
TDTamara Diesch
Tamara Diesch
F(for the Swiss Pediatric Oncology Group (SPOG)
for the Swiss Pediatric Oncology Group (SPOG)

4 September 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RKRahel Kasteler
Rahel Kasteler
AWAnnette Weiss
Annette Weiss
MSMatthias Schindler
Matthias Schindler
GSGrit Sommer
Grit Sommer
PLPhilipp Latzin
Philipp Latzin
S(Swiss Pediatric Oncology Group (SPOG)
Swiss Pediatric Oncology Group (SPOG)

12 December 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AWAnnette Weiss
Annette Weiss
RKRahel Kuonen
Rahel Kuonen
HBHanna Brockmeier
Hanna Brockmeier
MGMichael Grotzer
Michael Grotzer
CCClaudia Candreia
Claudia Candreia
S(Swiss Pediatric Oncology Group (SPOG)
Swiss Pediatric Oncology Group (SPOG)

19 June 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
SSSven Strebel
Sven Strebel
LMLuzius Mader
Luzius Mader
TSTomáš Sláma
Tomáš Sláma
NWNicolas Waespe
Nicolas Waespe
AWAnnette Weiss
Annette Weiss
CKClaudia E. Kuehni
Claudia E. Kuehni
Background: Hearing loss is a potential side effect from childhood cancer treatment. We described the severity of hearing loss assessed by audiometry in a representative national cohort of childhood cancer survivors (CCS) and identified clinical risk factors.Procedure: We included all CCS from the Swiss Childhood Cancer Registry who were diagnosed ≤18 age and treated with platinum‐based chemotherapy between 1990 and 2014. We extracted audiograms, treatment‐related information, and demographic data from medical records. Two reviewers independently assessed the severity of hearing loss at latest follow‐up using the Münster Ototoxicity Scale. We used ordered logistic regression to identify clinical risk factors for severity of hearing loss.Results: We analyzed data from 270 CCS. Median time from cancer diagnosis to last audiogram was 5 years (interquartile range 2.5–8.1 years). We found 53 (20%) CCS with mild, 78 (29%) with moderate, and 75 (28%) with severe hearing loss. Higher severity grades were associated with (a) younger age at cancer diagnosis (odds ratio [OR] 5.4, 95% confidence interval [CI]: 2.5–12.0 for 450 mg/m2); (d) concomitant cranial radiation therapy (CRT) (OR 4.4, 95% CI: 2.5–7.8); and (e) hematopoietic stem cell transplantation (HSCT) (OR 2.7, 95% CI: 1.0–7.2).Conclusion: Three of four CCS treated with platinum‐based chemotherapy experienced some degree of hearing loss. We recommend closely monitoring patient's hearing function if treated at a young age with high cumulative cisplatin doses, and concomitant CRT as part of long‐term care.